The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

If your constipation lasts for more than three days, speak with your doctor about options to help. You might need to add a ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

But given the evidence in total, Al-Aly says, “I’m more encouraged about the future of GLP-1 and its potential promise.” The ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...